The relationship between neutrophil-lymphocyte ratio (NLR) Background: with outcome is a complex issue. A high NLR reflects systemic inflammation. This study aimed to estimate the relationship between NLR, and platelet-lymphocyte ratio (PLR) in disease-free survival (DFS).
Introduction
Worldwide, breast cancer is the most diagnosed cancer type among women 1 . Animal models suggest "immune-editing" in which activation of immune mechanisms control the tumor, but over time lead to the selection of tumor cells that escape the immune pressure and grow progressively 2 . Most tumor antigens identify as non-mutated self-antigens. Tumors are heterogeneous, and the antigens on cells of one tumor are variable, even within the same patient, so the down-regulation of major histocompatibility complex molecules and other components of the antigen-presentation process can occur 1 . Tumors also do not express the ligands recognized by innate immune cells that microbes express or the co-stimulatory ligands necessary to stimulate adaptive T cells 2 . The expression of Fas ligand by some tumor cells help to maintain a state of immune privilege that induce apoptosis. Tumor cells lead to the release of many cytokines and soluble factors, such as prostaglandin E2, that are not conducive to antitumor immunity. Cancer-associated factors have been shown to inhibit the production and stimulatory capacity of tumor cells 3 . T-helper cell responses skewed toward a Th2 phenotype, lead to inhibition of the Th1 response and cellular immunity that mediates tumor rejection 4 .
The evidence of the relationship between inflammation and cancers prognosis has increased in past years, especially gastrointestinal tumors and non-small-cell lung cancers, and even breast cancers. The systemic inflammatory responses may mimic biochemical or hematological markers, such as raised C-reactive protein and the elevation of white blood cells, neutrophils, and platelets. Elevation of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in breast cancer patients is not well studied in Iraq. This relationship is a complex and multifactorial process that is still poorly understood, but a high NLR may reflect systemic inflammation in enhancing angiogenesis, tumor growth and development of metastasis. Therefore, this study aimed to estimate the relationship between NLR, PLR and disease-free survival (DFS) in breast cancer patients in Iraq.
Methods

Study design and setting
This is a cross-sectional retrospective study. Breast cancer patients who were treated at Babylon Oncology Center, Baghdad, Iraq from January 2009 to September 2014 were included in this study. The data was collected between May 2017 and April 2018. Tumor stage up to stage IIA (T1-T2, N0/ T1,  N1) ; follow-up for at least 36 months; availability of pretreatment complete blood count (CBC) with differential count.
Participants
Inclusion criteria:
Exclusion criteria: Locally advanced and metastatic breast cancer (T3-T4, N1-N3, M1); neoadjuvant treated patients; patients with data lacking for follow-up and pretreatment CBC with differential count; known causes of neutrophilia (those who already have this disease such as infections, inflammation, burns, heart attack, and drugs, e.g. steroids).
Data sources
The following data were collected from patient files: age, diagnosis date, date of recurrence and/or metastasis, follow-up, histological tumor type, tumor size, node metastasis stage, histological differentiation degree, estrogen and/or progesterone receptor expression, HER2 neu status, and metastasis site.
Statistical methods
The statistical analysis used the following tests: Anderson darling test, a statistical test of whether a given sample of data is drawn from a given probability distribution; Kaplan-Meier analysis, a non-parametric statistic used to estimate the survival function from lifetime data, which was used to assess DFS; hazard ratio (HR), the ratio of the hazard rates corresponding to the conditions described by two levels of an explanatory variable; ROC curve, a performance measurement for classification of problems at various thresholds settings; sensitivity analysis for test quality; and specificity analysis for test extension. SPSS 20.0 software package was used to for statistical analysis. P-value of <0.05 was considered significant. Patients who had missing data for variables were excluded from the analysis.
Ethical considerations
The Medical Ethical Committee of The Iraqi Board for Medical Specializations approved this study [CODE: 2015; date, 24-09-2013]. Participant consent was waived by the committee, since only patient files were reviewed.
Results
Out of a total of 1167 case files only 102 patients fit the eligibility criteria and completed the study, with a mean age of 50.4 ± 11.7 years (range, 23-75 years, the rest of the disease characteristic illustrated in (Table 1) . Local recurrence had the lowest rate, while combined local and distant recurrence had the highest rate ( Table 1 ). The median DFS was 62 months with 5 years DFS in 52.5% patients, patients with stage N0 had a significantly higher DFS compared to stage N1, and those patients with a positive hormonal status have a significantly better DFS compared to those with a negative hormonal status (Table 2; Figures 1A-D) . NLR had the highest discrimination ability to predict recurrence (since AUC between 0.7 -0.79), while the rest of the variables show poor discrimination ability, as illustrated in Table 3 and Table 4 and Figures 1E and F. NLR fair specificity (76.9%) with lower sensitivity (62.2%), with optimal cut point of >2.194 to predict all recurrence. NLR also showed similar predictability for distant metastasis, while for local recurrence NLR had poor ability to predict local recurrence (Table 5 and  Table 6 ; Figure 1G and Figure 2 ). Table 7 shows uni-and multivariate analysis of predictors of DFS with a significant p-value (p=0.007) for NLR, which means that it is an independent risk factor ( Figure 3 ).
Discussion
This is the first study to show an association between high NLR and poor prognosis in Iraqi breast cancer patients. A higher NLR independently reflected a higher risk of local recurrence and distant metastasis in women with early breast cancer with a cutoff point of 2.194.
We found significant differences in DFS (16 months) according to our NLR cut off point with significant p-value (p=0.004).
The role of lymphocytes in cancer is exemplified by the strong association between high densities of tumor-infiltrating lymphocytes and better responses to both cytotoxic treatments and outcome in patients 5, 6 . Two meta-analysis studies have confirmed the association between elevated NLR and poor prognosis for breast cancer 7, 8 ; however, studies about these values are rare and not done in Iraq. In this study, we validated the usefulness of high NLR in early stage breast cancer up to stage IIA and to estimate DFS for at least 36 months follow-up.
In our univariate and multivariate analysis, we found hazard ratio (HR) for NLR 2.5 with significant p-value (p=0.007), while in the univariate analysis the nodal status and hormonal status were significant as dependent prognostic factors. Comparing our result with Ethier et al., a meta-analysis which comprised patients with reported HRs for DFS, and included only non-metastatic cases 8 , our result has the same significance with good sample size and follow-up period; however, we couldn't calculate overall survival (OS). Although another study shown that PLR was not related with DFS or OS in women 9 , in our study PLR was neither sensitive nor specific with non-significant p-value, so it will not considered as a prognostic index.
Conclusion
The role of NLR is a prognostic marker and elevated NLR is correlated with poor DFS in early breast cancer patients. 
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